Unless the initial conditions be adjusted so as to make A = o exactly, x will ultimately increase indefinitely with t.
By this mechanism, efalizumab inhibits the binding of LFA-1 to ICAM-1, which interferes with T lymphocytes adhesion to other cell types.
This syndrome is often associated with T lymphocyte deficiencies.
